Nidal Al-Huniti1, Klas Petersson2, Weifeng Tang1, Eric Masson1, Jianguo Li1. 1. Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicine and Early Development, AstraZeneca, Waltham, MA, USA. 2. qPharmetra, LLC, Stockholm, Sweden.
Abstract
AIMS: A multistudy analysis of cediranib, a potent, selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), was conducted to establish population exposure-safety models for the relationship of cediranib exposure to the safety endpoints, diastolic and systolic blood pressure (DBP and SBP) and diarrhoea in cancer patients. These models were applied to predict safety outcomes for different cediranib dose regimens. METHODS: Models for hypertension and diarrhoea were constructed based on data from 10 Phase I and three Phase II studies comprising 631 cancer patients following cediranib once-daily oral dosing. Daily DBP and SBP were simultaneously characterized using indirect response models for predicted cediranib concentration-time courses, while daily diarrhoea events were modelled as ordered categorical variables with a proportional odds model with a Markov element for predicted average cediranib concentrations. RESULTS: For 20 mg cediranib once-daily oral administration, the mean increase in DBP and SBP was predicted to be 7 (95% CI 3-13) and 8 mmHg (95% CI 3-16), respectively, while the probability of mild diarrhoea, but not the severity, was predicted to increase over time. Severe diarrhoea was predicted to be resolved rapidly upon discontinuation of cediranib treatment. CONCLUSIONS: Maximum blood pressure increase was observed within the first few days of cediranib treatment, consistent with the pharmacokinetic profile of cediranib reaching steady state in about 5 days. The probability of diarrhoea increased with cediranib concentration but was far more dependent on the status of diarrhoea predicted on the previous day.
AIMS: A multistudy analysis of cediranib, a potent, selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), was conducted to establish population exposure-safety models for the relationship of cediranib exposure to the safety endpoints, diastolic and systolic blood pressure (DBP and SBP) and diarrhoea in cancerpatients. These models were applied to predict safety outcomes for different cediranib dose regimens. METHODS: Models for hypertension and diarrhoea were constructed based on data from 10 Phase I and three Phase II studies comprising 631 cancerpatients following cediranib once-daily oral dosing. Daily DBP and SBP were simultaneously characterized using indirect response models for predicted cediranib concentration-time courses, while daily diarrhoea events were modelled as ordered categorical variables with a proportional odds model with a Markov element for predicted average cediranib concentrations. RESULTS: For 20 mg cediranib once-daily oral administration, the mean increase in DBP and SBP was predicted to be 7 (95% CI 3-13) and 8 mmHg (95% CI 3-16), respectively, while the probability of mild diarrhoea, but not the severity, was predicted to increase over time. Severe diarrhoea was predicted to be resolved rapidly upon discontinuation of cediranib treatment. CONCLUSIONS: Maximum blood pressure increase was observed within the first few days of cediranib treatment, consistent with the pharmacokinetic profile of cediranib reaching steady state in about 5 days. The probability of diarrhoea increased with cediranib concentration but was far more dependent on the status of diarrhoea predicted on the previous day.
Authors: Peter Mulders; Robert Hawkins; Paul Nathan; Igle de Jong; Susanne Osanto; Emilio Porfiri; Andrew Protheroe; Carla M L van Herpen; Bijoyesh Mookerjee; Laura Pike; Juliane M Jürgensmeier; Martin E Gore Journal: Eur J Cancer Date: 2012-01-28 Impact factor: 9.162
Authors: Sandra R Brave; Kirsty Ratcliffe; Zena Wilson; Neil H James; Sue Ashton; Anna Wainwright; Jane Kendrew; Philippa Dudley; Nicola Broadbent; Graham Sproat; Sian Taylor; Claire Barnes; Jeffrey C Silva; Charles L Farnsworth; Laurent Hennequin; Donald J Ogilvie; Juliane M Jürgensmeier; Masabumi Shibuya; Stephen R Wedge; Simon T Barry Journal: Mol Cancer Ther Date: 2011-03-25 Impact factor: 6.261
Authors: Veli-Matti Leppänen; Andrea E Prota; Michael Jeltsch; Andrey Anisimov; Nisse Kalkkinen; Tomas Strandin; Hilkka Lankinen; Adrian Goldman; Kurt Ballmer-Hofer; Kari Alitalo Journal: Proc Natl Acad Sci U S A Date: 2010-02-09 Impact factor: 11.205
Authors: Hester van Cruijsen; Emile E Voest; Cornelis J A Punt; Klaas Hoekman; Petronella O Witteveen; Martijn R Meijerink; Thomas A Puchalski; Jane Robertson; Owain Saunders; Juliane M Jürgensmeier; Carla M L van Herpen; Giuseppe Giaccone Journal: Eur J Cancer Date: 2010-01-12 Impact factor: 9.162
Authors: Scott A Laurie; Isabelle Gauthier; Andrew Arnold; Frances A Shepherd; Peter M Ellis; Eric Chen; Glenwood Goss; Jean Powers; Wendy Walsh; Dongsheng Tu; Jane Robertson; Thomas A Puchalski; Lesley Seymour Journal: J Clin Oncol Date: 2008-04-10 Impact factor: 44.544
Authors: Caroline A Heckman; Tanja Holopainen; Maria Wirzenius; Salla Keskitalo; Michael Jeltsch; Seppo Ylä-Herttuala; Stephen R Wedge; Juliane M Jürgensmeier; Kari Alitalo Journal: Cancer Res Date: 2008-06-15 Impact factor: 12.701